BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 27833153)

  • 1. TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis.
    Liu C; Liu Z; Chen T; Zeng W; Guo Y; Huang T
    Sci Rep; 2016 Nov; 6():36990. PubMed ID: 27833153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Coexistent BRAF
    Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
    Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis.
    Yin DT; Yu K; Lu RQ; Li X; Xu J; Lei M; Li H; Wang Y; Liu Z
    Clin Endocrinol (Oxf); 2016 Aug; 85(2):299-305. PubMed ID: 26732020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.
    Myung JK; Kwak BK; Lim JA; Lee MC; Kim MJ
    Cancer Res Treat; 2016 Jul; 48(3):942-7. PubMed ID: 26727717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.
    Vuong HG; Altibi AM; Duong UN; Ngo HT; Pham TQ; Tran HM; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R; Kondo T
    Tumour Biol; 2017 Oct; 39(10):1010428317713913. PubMed ID: 29037127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas.
    Bullock M; Ren Y; O'Neill C; Gill A; Aniss A; Sywak M; Sidhu S; Delbridge L; Learoyd D; de Vathaire F; Robinson BG; Clifton-Bligh RJ
    Clin Endocrinol (Oxf); 2016 Aug; 85(2):283-90. PubMed ID: 26667986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors.
    Matsuse M; Yabuta T; Saenko V; Hirokawa M; Nishihara E; Suzuki K; Yamashita S; Miyauchi A; Mitsutake N
    Sci Rep; 2017 Feb; 7():41752. PubMed ID: 28150740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
    Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
    Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
    Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
    Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis.
    Vuong HG; Altibi AMA; Duong UNP; Hassell L
    Clin Endocrinol (Oxf); 2017 Nov; 87(5):411-417. PubMed ID: 28666074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.
    Bu R; Siraj AK; Divya SP; Kong Y; Parvathareddy SK; Al-Rasheed M; Al-Obaisi KAS; Victoria IG; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
    Int J Cancer; 2018 May; 142(10):2028-2039. PubMed ID: 29266240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis.
    Liu Z; Zeng W; Chen T; Guo Y; Zhang C; Liu C; Huang T
    Oncotarget; 2017 Jan; 8(4):6222-6232. PubMed ID: 28009980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [
    Yang T; Chen C; Pan NF; Sun LY; Jiang XL; Li JN; Tang Y; Jiang Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.
    Yang J; Gong Y; Yan S; Chen H; Qin S; Gong R
    Endocrine; 2020 Jan; 67(1):44-57. PubMed ID: 31655978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
    Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
    Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of TERT promoter and BRAF mutations in TIR-4 and TIR-5 thyroid cytology.
    Censi S; Barollo S; Grespan E; Watutantrige-Fernando S; Manso J; Iacobone M; Casal Ide E; Galuppini F; Fassina A; Bertazza L; Vianello F; Pennelli G; Mian C
    Eur J Endocrinol; 2019 Jul; 181(1):1-11. PubMed ID: 31042674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutations and long-term survival in patients with thyroid cancer.
    Kim TH; Kim YE; Ahn S; Kim JY; Ki CS; Oh YL; Kim K; Yun JW; Park WY; Choe JH; Kim JH; Kim JS; Kim SW; Chung JH
    Endocr Relat Cancer; 2016 Oct; 23(10):813-23. PubMed ID: 27528624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
    Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS
    Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
    Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
    [No Abstract]   [Full Text] [Related]  

  • 20. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
    Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
    Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.